RBC Capital Markets has raised its price target on Haleon, the British consumer healthcare giant behind brands like Sensodyne and Panadol, to £3.90. The move comes after the company posted a mixed set of first-half results: revenue grew, but reported operating profit slipped.
Mixed numbers, brighter underlying trend
Haleon's first-half revenue rose 2.2% to £5.60 billion, while reported operating profit fell 2.6% to £1.17 billion. That headline dip might look concerning, but the bank's decision to lift its target suggests it sees more encouraging signs beneath the surface.
The key distinction here is between "reported" and "adjusted" figures. Reported numbers include one-off items, restructuring costs, and currency swings. Adjusted figures strip those out to show how the core business is performing. Haleon's adjusted operating profit rose 8.2% at constant currency to £1.36 billion. Constant currency simply means the effect of exchange-rate movements has been removed, so analysts can judge the business on its own merits.
So while the reported profit fell, the underlying profitability improved. That's likely why RBC felt comfortable nudging its target price up, even after a "mixed" half.
What this means for investors
For everyday investors, the takeaway is that analyst price targets are opinions, not guarantees. A single bank's move can influence sentiment, but it's just one view. Haleon's shares will react to a range of factors, including how well its brands perform, competition, and broader market conditions.
Consumer healthcare is generally seen as a defensive sector—people buy toothpaste and painkillers regardless of the economic cycle. That can make companies like Haleon attractive to investors seeking stability. However, the company also faces challenges, such as input cost inflation and currency volatility, which can weigh on reported profits.
RBC's target of £3.90 implies some upside from current levels, but investors should remember that price targets are often set with a 12-month horizon and can be revised as new information comes in.
Broader context
Haleon was spun off from GSK in 2022, becoming one of the world's largest standalone consumer health companies. Its portfolio includes well-known names like Advil, Centrum, and Sensodyne. The company has been focusing on innovation and cost efficiency to drive growth.
The mixed results come at a time when consumer spending is under pressure in many markets due to inflation. Yet, demand for everyday health products tends to be resilient. Investors will be watching whether Haleon can maintain its adjusted profit growth and manage costs effectively.
RBC's move is part of a broader pattern of analysts adjusting targets based on earnings reports. For instance, RBC also raised its Allianz target after a strong quarter, showing the bank is actively updating its views across sectors.
In the consumer space, other analysts have been reacting to company performance too. UBS lifted its Brinker target on restaurant momentum, while United Securities cut Agthia's target after a profit miss. These moves highlight how analysts parse quarterly numbers to set expectations.
What to watch next
Investors should keep an eye on Haleon's next earnings report, as well as any updates on currency trends and input costs. The company's ability to grow adjusted profit while navigating a tough consumer environment will be key.
Also worth watching is whether other banks follow RBC's lead. If more analysts raise their targets, it could signal growing confidence in Haleon's prospects. Conversely, if the reported profit decline worries others, we might see downgrades.
For now, RBC's modest target hike suggests a cautiously optimistic view. But as always, it's wise to do your own research and consider how Haleon fits into your overall portfolio.
